Download PDF
Semin Liver Dis 2012; 32(02): 167-176
DOI: 10.1055/s-0032-1316472
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Toxicity of Antiretroviral Drugs

Michelle Jones
1   Section on Infectious Diseases, Department of Internal Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC
,
Marina Núñez
1   Section on Infectious Diseases, Department of Internal Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC
› Author Affiliations
Further Information

Publication History

Publication Date:
03 July 2012 (online)

    Permissions and Reprints

Abstract

Drug-induced liver injury (DILI) associated with antiretroviral treatment has represented an important side effect since the beginning of the HAART era. The lack of standard definition and specific markers makes assessment of DILI very challenging. Several clinical syndromes of DILI have been described over the years; the pathogenic mechanisms are not fully understood. Better knowledge of DILI, identification of high-risk patients using pharmacogenetics, and the availability of antiretroviral agents with improved safety profile have all contributed to decrease the incidence of DILI and to ameliorate its effects. Nevertheless, with an aging human immunodeficiency virus- (HIV-) infected population and increased survival, DILI will probably continue to represent a relevant entity in e HIV therapeutic management.

Keywords

antiretroviral therapy - hepatotoxicity - HIV - drug-induced liver injury - DILI
 

  • References

  • 1 Aithal GP, Watkins PB, Andrade RJ , et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89 (6) 806-815
    CrossrefPubMedGoogle Scholar
  • 2 Fontana RJ, Seeff LB, Andrade RJ , et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52 (2) 730-742
    CrossrefPubMedGoogle Scholar
  • 3 Rockey DC, Seeff LB, Rochon J , et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51 (6) 2117-2126
    CrossrefPubMedGoogle Scholar
  • 4 Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26 (3) 664-669
    CrossrefPubMedGoogle Scholar
  • 5 Naranjo CA, Busto U, Sellers EM , et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2) 239-245
    CrossrefPubMedGoogle Scholar
  • 6 Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 2010; 245 (1) 134-142
    CrossrefPubMedGoogle Scholar
  • 7 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2) 272-276
    CrossrefPubMedGoogle Scholar
  • 8 Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011; 53 (4) 1377-1387
    CrossrefPubMedGoogle Scholar
  • 9 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46 (11) 1323-1330
    CrossrefPubMedGoogle Scholar
  • 10 AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996
    Google Scholar
  • 11 Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283 (1) 74-80
    CrossrefPubMedGoogle Scholar
  • 12 Guidance for industry drug-induced liver injury: premarketing clinical evaluation July 2009. . Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm . Accessed November 15, 2011
    PubMedGoogle Scholar
  • 13 M'Kada H, Munteanu M, Perazzo H , et al; DILI group of the SAFE-T consortium. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol 2011; 60 (3) 290-295
    CrossrefPubMedGoogle Scholar
  • 14 Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52 (3) 1143-1155
    CrossrefPubMedGoogle Scholar
  • 15 Lamivudine full prescribing information. Research Triangle Park, NC: GlaxoSmithKline; . Available at: http://www.epivir.com . Accessed October 17, 2011
    Google Scholar
  • 16 Tenofovir full prescribing information. Foster City, CA: Gilead Sciences, Inc; . Available at: http://www.viread.com . Accessed October 17, 2011
    Google Scholar
  • 17 Zidovudine full prescribing information. Research Triangle Park, NC: GlaxoSmithKline; . Available at: http://www.retrovir.com . Accessed October 17, 2011
    Google Scholar
  • 18 Emtricitabine full prescribing information. Foster City, CA: Gilead Sciences, Inc; . Available at: http://www.emtriva.com . Accessed October 17, 2011
    Google Scholar
  • 19 Abacavir full prescribing information. Research Triangle Park, NC: GlaxoSmithKline; . Available at: http://www.ziagen.com . Accessed October 17, 2011
    Google Scholar
  • 20 Didanosine full prescribing information. Princeton, NJ: Bristol-Myers Squibb; . Available at: http://www.videx.com . Accessed October 17, 2011
    Google Scholar
  • 21 Stavudine full prescribing information. Princeton, NJ: Bristol-Myers Squibb; . Available at: http://www.zerit.com . Accessed October 17, 2011
    Google Scholar
  • 22 Rilpivirine full prescribing information. Raritan, NJ: Tibotec, INc; . Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf . Accessed October 17, 2011
    Google Scholar
  • 23 Etravirine full prescribing information. Rarritan, NJ: Tibotec Therapeutics; . Available at: http://www.intelence.com . Accessed October 17, 2011
    Google Scholar
  • 24 Delavirdine full prescribing information. New York, NY: Pfizer, Inc; . Available at: http://www.rescriptor.com . Accessed January 7, 2010
    Google Scholar
  • 25 Efavirenz full prescribing information. Princeton, NJ: Bristol-Myers Squibb; . Available at: http://www.sustiva.com . Accessed October 17, 2011
    Google Scholar
  • 26 Nevirapine full prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; . Available at: http://www.viramune.com . Accessed October 17, 2011
    Google Scholar
  • 27 Nelfinavir full prescribing information. La Jolla, CA: Agouron Pharmaceuticals, Inc; . Available at: http://www.viracept.com . Accessed October 17, 2011
    Google Scholar
  • 28 Indinavir full prescribing information. Whitehouse Station, NJ: MERCK & CO; . Available at: http://www.crixivan.com . Accessed October 17, 2011
    Google Scholar
  • 29 Darunavir full prescribing information. Raritan, NJ: Tibotec Therapeutics; . Available at: http://www.prezista.com . Accessed October 17, 2011
    Google Scholar
  • 30 Fosamprenavir full prescribing information. Research Triangle Park, NC: GlaxoSmithKline; . Available at: http://www.lexiva.com . Accessed October 17, 2011
    Google Scholar
  • 31 Ritonavir full prescribing information. North Chicago, IL: Abbott Laboratories; . Available at: http://www.norvir.com . Accessed October 17, 2011
    Google Scholar
  • 32 Atazanavir full prescribing information. Princeton, NJ: Bristol-Myers Squibb; . Available at: http://www.reyataz.com . Accessed October 17, 2011
    Google Scholar
  • 33 Tipranavir full prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; . Available at: http://www.aptivus.com . Accessed October 17, 2011
    Google Scholar
  • 34 Lopinavir full prescribing information. North Chicago, IL: Abbott Laboratories; . Available at: http://www.kaletra.com . Accessed October 17, 2011
    Google Scholar
  • 35 Maraviroc full prescribing information. New York: Pfizer Labs; . Available at: http://www.selzentry.com . Accessed October 17, 2011
    Google Scholar
  • 36 Raltegravir full prescribing information. Whitehouse Station, NJ: MERCK & CO; . Available at: http://www.isentress.com . Accessed October 17, 2011
    Google Scholar
  • 37 Enfuvirtide full prescribing information. Durham, NC: Trimeris, Inc; . Available at: http://www.fuzeon.com . Accessed October 17, 2011
    Google Scholar
  • 38 Saquinavir full prescribing information. Nutley, NJ: Roche Laboratories Inc; . Available at: http://www.invirase.com . Accessed October 17, 2011
    Google Scholar
  • 39 den Brinker M, Wit FW, Wertheim-van Dillen PM , et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14 (18) 2895-2902
    CrossrefPubMedGoogle Scholar
  • 40 Heil EL, Townsend ML, Shipp K, Clarke A, Johnson MD. Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients. Aids Res Treat 2010; 2010: 856542
    PubMedGoogle Scholar
  • 41 Chihrin S, Antoniou T, Raboud J , et al. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy. AIDS Patient Care STDS 2007; 21 (7) 469-478
    CrossrefPubMedGoogle Scholar
  • 42 Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43 (3) 320-323
    CrossrefPubMedGoogle Scholar
  • 43 Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186 (1) 23-31
    CrossrefPubMedGoogle Scholar
  • 44 Lamar ZS, Núnez M. Higher risk of severe drug-induced liver injury among Hispanic HIV-infected patients after initiation of highly active antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic) 2011; 10 (3) 183-186 (JIAPAC)
    CrossrefPubMedGoogle Scholar
  • 45 Kovari H, Ledergerber B, Battegay M , et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50 (4) 502-511
    CrossrefPubMedGoogle Scholar
  • 46 Shores NJ, Maida I, Perez-Saleme L, Núñez M. Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. J Int Assoc Physicians AIDS Care (Chic) 2010; 9 (1) 15-19
    CrossrefPubMedGoogle Scholar
  • 47 Crum-Cianflone N, Dilay A, Collins G , et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50 (5) 464-473
    CrossrefPubMedGoogle Scholar
  • 48 Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192 (11) 1943-1949
    CrossrefPubMedGoogle Scholar
  • 49 Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 2008; 47 (4) 441-448
    CrossrefPubMedGoogle Scholar
  • 50 Currier J, Spino C, Grimes J , et al. Differences between women and med in adverse events and CD4 responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24: 316-324
    PubMedGoogle Scholar
  • 51 Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003; 11 (2) 55-59
    PubMedGoogle Scholar
  • 52 Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1) S21-S33
    CrossrefPubMedGoogle Scholar
  • 53 Sanne I, Mommeja-Marin H, Hinkle J , et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191 (6) 825-829
    CrossrefPubMedGoogle Scholar
  • 54 Kesselring AM, Wit FW, Sabin CA , et al; Nevirapine Toxicity Multicohort Collaboration. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009; 23 (13) 1689-1699
    CrossrefPubMedGoogle Scholar
  • 55 Wit FW, Kesselring AM, Gras L , et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis 2008; 46 (6) 933-940
    CrossrefPubMedGoogle Scholar
  • 56 Martin AM, Nolan D, James I , et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19 (1) 97-99
    CrossrefPubMedGoogle Scholar
  • 57 Martin AM, Nolan D, Gaudieri S , et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101 (12) 4180-4185
    CrossrefPubMedGoogle Scholar
  • 58 Wyen C, Hendra H, Vogel M , et al; German Competence Network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61 (4) 914-918
    CrossrefPubMedGoogle Scholar
  • 59 Leger P, Dillingham R, Beauharnais CA , et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis 2009; 200 (6) 955-964
    CrossrefPubMedGoogle Scholar
  • 60 Yimer G, Amogne W, Habtewold A , et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2011; ; Aug 23. doi: 10.1038/tpj.2011.34. [Epub ahead of print]
    PubMedGoogle Scholar
  • 61 Mallal S, Phillips E, Carosi G , et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358 (6) 568-579
    CrossrefPubMedGoogle Scholar
  • 62 Saag M, Balu R, Phillips E , et al; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46 (7) 1111-1118
    CrossrefPubMedGoogle Scholar
  • 63 Johnson S, Chan J, Bennett C.. Hepatotoxicity after prophylaxis with a nevirapine containing antiretroviral regimen. Ann Intern Med 2002; 137 (2) 146-147
    CrossrefPubMedGoogle Scholar
  • 64 Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures—worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49 (51-52) 1153-1156
    PubMedGoogle Scholar
  • 65 Pavel S, Burty C, Alcaraz I , et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS 2007; 21 (2) 268-269
    CrossrefPubMedGoogle Scholar
  • 66 Anonymous. Liver toxicity warning for darunavir. AIDS Patient Care STDS 2008; 22 (4) 346
    PubMedGoogle Scholar
  • 67 Claudio GA, Martin AF, de Dios Perrino S, Velasco AA. DRESS syndrome associated with nevirapine therapy. Arch Intern Med 2001; 161 (20) 2501-2502
    CrossrefPubMedGoogle Scholar
  • 68 Leung JM, O'Brien JG, Wong HK, Winslow DL. Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male. Ann Pharmacother 2008; 42 (3) 425-429
    CrossrefPubMedGoogle Scholar
  • 69 Turkova A, Ball C, Gilmour-White S, Rela M, Mieli-Vergani G. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. J Antimicrob Chemother 2009; 63 (3) 623-625
    CrossrefPubMedGoogle Scholar
  • 70 Montaner JS, Reiss P, Cooper D , et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279 (12) 930-937
    CrossrefPubMedGoogle Scholar
  • 71 Carr A, Vella S, de Jong MD , et al; The Dutch-Italian-Australian Nevirapine Study Group. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996; 10 (6) 635-641
    CrossrefPubMedGoogle Scholar
  • 72 D'Aquila R, Hughes M, Johnsons V , et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996; 124: 1019-1030
    CrossrefPubMedGoogle Scholar
  • 73 Hernandez J, Cutrell A, Edwards M, Fleming J, Powell W, Scott T. Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials. Paper presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL
    PubMedGoogle Scholar
  • 74 Hetherington S, McGuirk S, Powell G , et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23 (10) 1603-1614
    CrossrefPubMedGoogle Scholar
  • 75 Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21 (18) 2455-2464
    CrossrefPubMedGoogle Scholar
  • 76 Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79 (4) 340-343
    CrossrefPubMedGoogle Scholar
  • 77 Batisse D, Duong Van Huyen JP, Piketty C , et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. AIDS 2002; 16 (17) 2370-2371
    CrossrefPubMedGoogle Scholar
  • 78 Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 2005; 24 (1) 5-15
    CrossrefPubMedGoogle Scholar
  • 79 Apostolova N, Blas-García A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol Sci 2011; 32 (12) 715-725
    CrossrefPubMedGoogle Scholar
  • 80 Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15 (6) 367-373
    CrossrefPubMedGoogle Scholar
  • 81 Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003; 23 (2) 167-172
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33 (4) 1009-1013
    CrossrefPubMedGoogle Scholar
  • 83 Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16 (10) 1341-1349
    CrossrefPubMedGoogle Scholar
  • 84 U.S. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for use of antiretroviral agents in HIV-1 infected adults and adolescents. January 10, 2011. Available at: http://www.aidsinfo.nih.gov/Guidelines/GuidelineHTML.aspx?GuidelineID=7&docID=1&NodeID=12 . Accessed October 11, 2011
    PubMedGoogle Scholar
  • 85 Brinkman K, ter Hoftede HJM. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev 1999; 1: 141-148
    PubMedGoogle Scholar
  • 86 ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11 (9) 611-616
    CrossrefPubMedGoogle Scholar
  • 87 Sulkowski MS, Mehta SH, Torbenson M , et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19 (6) 585-592
    CrossrefPubMedGoogle Scholar
  • 88 Rodríguez-Torres M, Govindarajan S, Solá R , et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48 (5) 756-764
    CrossrefPubMedGoogle Scholar
  • 89 Guaraldi G, Squillace N, Stentarelli C , et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47 (2) 250-257
    CrossrefPubMedGoogle Scholar
  • 90 Woreta T, Sutcliffe C, Mehta S , et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-817
    CrossrefPubMedGoogle Scholar
  • 91 Szabo G, Zakhair S. Mechanisms of alcohol-related hepatotoxicity in human-immunodeficiency-virus-infected patients. World J Gastroenterol 2011; 17: 2500-2506
    CrossrefPubMedGoogle Scholar
  • 92 Bani-Sadr F, Carrat F, Bedossa P , et al; ANRS HC02 - Ribavic Study team. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20 (4) 525-531
    CrossrefPubMedGoogle Scholar
  • 93 Neau D, Winnock M, Castéra L , et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2007; 45 (2) 168-173
    CrossrefPubMedGoogle Scholar
  • 94 Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54 (3) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 95 Maida I, Núñez M, Ríos MJ , et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42 (2) 177-182
    CrossrefPubMedGoogle Scholar
  • 96 Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007; 21 (8) 1066-1068
    CrossrefPubMedGoogle Scholar
  • 97 Chang PE, Miquel R, Blanco JL , et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104 (7) 1707-1714
    CrossrefPubMedGoogle Scholar
  • 98 Diaz HA, Callejo AM, Martinez A, Rodriguez JFG. Non-cirrhotic portal hypertension in HIV-infected patients: A new challenge in antiretroviral therapy. AIDS 2011; 5: 59-61
    PubMedGoogle Scholar
  • 99 Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102 (11) 2536-2540
    CrossrefPubMedGoogle Scholar
  • 100 Chang PE, Garcia-Pagan JC. Idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis 2010; 50 (1) 127-128 , author reply 128–129
    CrossrefPubMedGoogle Scholar
  • 101 Schiano TD, Uriel A, Dieterich DT, Fiel MI. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch 2011; 458 (2) 231-235
    CrossrefPubMedGoogle Scholar
  • 102 Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS 2007; 21 (11) 1494-1495
    CrossrefPubMedGoogle Scholar
  • 103 Sandrine PF, Sylvie A, André E, Abdoulaye D, Bernard L, André C. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?. AIDS 2007; 21 (11) 1498-1499
    CrossrefPubMedGoogle Scholar
  • 104 Saifee S, Joelson D, Braude J , et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6: 1167-1169
    CrossrefPubMedGoogle Scholar
  • 105 Mallet V, Blanchard P, Verkarre V , et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21 (2) 187-192
    CrossrefPubMedGoogle Scholar
  • 106 Kovari H, Ledergerber B, Peter U , et al; Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49 (4) 626-635
    CrossrefPubMedGoogle Scholar
  • 107 Scourfield A, Waters L, Holmes P , et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22 (6) 324-328
    CrossrefPubMedGoogle Scholar
  • 108 Vispo E, Moreno A, Maida I , et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24 (8) 1171-1176
    CrossrefPubMedGoogle Scholar
  • 109 Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011; 24 (1) 12-18
    CrossrefPubMedGoogle Scholar
  • 110 Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357 (9266) 1412-1414
    CrossrefPubMedGoogle Scholar
  • 111 Maida I, Garcia-Gasco P, Sotgiu G , et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13 (1) 103-107
    PubMedGoogle Scholar
  • 112 Hillaire S, Bonte E, Denninger MH , et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51 (2) 275-280
    CrossrefPubMedGoogle Scholar
  • 113 Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23 (2) 183-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 114 Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18 (17) 2277-2284
    CrossrefPubMedGoogle Scholar
  • 115 Gathe Jr JC, Pierone G, Piliero P , et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses 2007; 23 (2) 216-223
    CrossrefPubMedGoogle Scholar
  • 116 van Leth F, Phanuphak P, Ruxrungtham K , et al; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363 (9417) 1253-1263
    CrossrefPubMedGoogle Scholar
  • 117 González de Requena D, Núñez M, Jiménez-Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16 (2) 290-291
    CrossrefPubMedGoogle Scholar
  • 118 Núñez M, González-Requena D, González-Lahoz J, Soriano V. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses 2003; 19 (3) 187-188
    CrossrefPubMedGoogle Scholar
  • 119 Kappelhoff BS, van Leth F, Robinson PA , et al; 2NN Study Group. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 2005; 10 (4) 489-498
    PubMedGoogle Scholar
  • 120 Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30 (1) 65-68
    PubMedGoogle Scholar
  • 121 Maida I, Babudieri S, Selva C , et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. AIDS Res Hum Retroviruses 2006; 22 (2) 139-143
    CrossrefPubMedGoogle Scholar
  • 122 Torti C, Lapadula G, Puoti M , et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr 2006; 41 (2) 180-185
    CrossrefPubMedGoogle Scholar
  • 123 Yunihastuti E, Lee S, Gani R , et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commending ART. Clin Immunol 2011; 139 (1) 32-39
    CrossrefPubMedGoogle Scholar
  • 124 John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?. AIDS 1998; 12 (17) 2289-2293
    CrossrefPubMedGoogle Scholar
  • 125 Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007; 334 (5) 334-341
    CrossrefPubMedGoogle Scholar
  • 126 Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis 2002; 186 (10) 1498-1502
    CrossrefPubMedGoogle Scholar
  • 127 Crane M, Oliver B, Matthews G , et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009; 199 (7) 974-981
    CrossrefPubMedGoogle Scholar
  • 128 Macías J, Castellano V, Merchante N , et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18 (5) 767-774
    CrossrefPubMedGoogle Scholar
  • 129 Fuster D, Planas R, Muga R , et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20 (12) 1293-1297
    CrossrefPubMedGoogle Scholar
  • 130 Sterling RK, Wilson MS, Sanyal AJ , et al. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol 2004; 2 (5) 432-439
    CrossrefPubMedGoogle Scholar
  • 131 Berenguer J, Bellón JM, Miralles P , et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46 (1) 137-143
    CrossrefPubMedGoogle Scholar
  • 132 Jones M, Núñez M. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS 2011; 6 (6) 546-552
    CrossrefPubMedGoogle Scholar
  • 133 McLean AJ, Cogger VC, Chong GC , et al. Age-related pseudocapillarization of the human liver. J Pathol 2003; 200 (1) 112-117
    CrossrefPubMedGoogle Scholar
  • 134 Labarga P, Soriano V, Vispo ME , et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196 (5) 670-676
    CrossrefPubMedGoogle Scholar
  • 135 Vispo E, Mena A, Maida I , et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010; 65 (3) 543-547
    CrossrefPubMedGoogle Scholar